Nephro Care

Why is Nephro Care India Ltd falling/rising?

As of 01-Sep, Nephro Care India Ltd's stock price is at 100.70, down 1.15 (-1.13%). The decline is due to underperformance against its sector, a significant drop in trading volume, and an 8.87% year-to-date decrease, indicating waning investor interest.

As of 01-Sep, Nephro Care India Ltd's stock price is currently at 100.70, reflecting a decrease of 1.15 (-1.13%). Despite a strong performance over the past week and month, where the stock has risen by 10.72% and 56.73% respectively, it is experiencing a decline today. This decline can be attributed to several factors. <BR><BR>Firstly, the stock has underperformed its sector by 0.54%. Additionally, there has been a significant drop in investor participation, with delivery volume on 31 August falling by 73.68% compared to the 5-day average. This reduction in trading activity may indicate waning investor interest, contributing to the stock's price decline. <BR><BR>Moreover, while Nephro Care is trading above its moving averages for various periods, the year-to-date performance shows a decline of 8.87%, which may also affect investor sentiment. Overall, the combination of underperformance relative to the sector, decreased trading volume, and a negative year-to-date trend are likely influencing the current downward movement in the stock price.

Which are the latest news on Nephro Care?

What does Nephro Care do?

Nephro Care India Ltd is a micro-cap healthcare company focused on hospital services, incorporated in 2014 and converted to a public company in 2024. As of June 2026, it reported net sales of 29 Cr and a net profit of 2 Cr, with a market cap of INR 169 Cr.

Overview:<BR>Nephro Care India Ltd operates in the hospital industry as a micro-cap company, focusing on providing healthcare services.<BR><BR>History:<BR>Nephro Care India Limited was incorporated on July 08, 2014, originally as a Private Limited Company. It later converted into a Public Limited Company, with the name changed to Nephro Care India Limited and a fresh Certificate of Incorporation issued on March 5, 2024. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 29 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 2 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 169 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 71.00<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.29<BR>- Return on Equity: 5.93%<BR>- Price to Book: 2.96<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Nephro Care?

Nephro Care's peers include Aprameya Enginee, Lotus Eye Hospital, Vaidya Sane, KHFM Hospitality, Maitreya Medica, Sangani Hospital, Aashka Hospitals, Abate As Indust, and Fortis Malar. Nephro Care has average management risk, excellent growth, and a 1-year return of -34.31%, better than Maitreya Medica but worse than Sangani Hospital.

Peers: The peers of Nephro Care are Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, KHFM Hospitality, Maitreya Medica., Sangani Hospital, Aashka Hospitals, Abate As Indust, and Fortis Malar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aprameya Enginee, while Average management risk is found at Nephro Care, and Below Average management risk is noted at Lotus Eye Hospit, Vaidya Sane, KHFM Hospitality, Maitreya Medica., Sangani Hospital, Aashka Hospitals, Abate As Indust, and Fortis Malar. Excellent growth is seen at Nephro Care and Sangani Hospital, Average growth is noted at Vaidya Sane, and Below Average growth is present at Aprameya Enginee, Lotus Eye Hospit, KHFM Hospitality, Maitreya Medica., Aashka Hospitals, Abate As Indust, and Fortis Malar. Good capital structure is found at Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, Nephro Care, and Sangani Hospital, while Below Average capital structure is observed at KHFM Hospitality, Maitreya Medica., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sangani Hospital at -21.52%, while the lowest is Maitreya Medica. at -53.58%. Nephro Care's 1-year return is -34.31%, which is better than Maitreya Medica. and worse than Sangani Hospital. Additionally, KHFM Hospitality, Maitreya Medica., and Fortis Malar have negative six-month returns.

How big is Nephro Care?

As of 31st August, Nephro Care India Ltd has a market capitalization of 169.00 Cr, with recent net sales of 73.27 Cr and a net profit of 1.96 Cr. Shareholder's funds are 53.48 Cr and total assets are valued at 68.28 Cr as of March 2025.

As of 31st August, Nephro Care India Ltd has a market capitalization of 169.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Nephro Care reported Net Sales of 73.27 Cr and a Net Profit of 1.96 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 53.48 Cr and Total Assets valued at 68.28 Cr.

How has been the historical performance of Nephro Care?

Nephro Care has experienced significant growth from March 2022 to March 2025, with net sales increasing from 3.42 Cr to 46.03 Cr, and total assets rising to 68.28 Cr. Despite fluctuations in profit metrics, the company shows a strong upward trend in financial performance and operational scaling.

Answer:<BR>The historical performance of Nephro Care shows significant growth over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Nephro Care's net sales have increased dramatically from 3.42 Cr in March 2022 to 46.03 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 3.42 Cr in March 2022 to 46.03 Cr in March 2025. The company's total expenditure also grew, reaching 40.16 Cr in March 2025 from just 3.30 Cr in March 2022. Operating profit, excluding other income, peaked at 5.87 Cr in March 2025, although it was slightly lower than the previous year's 6.47 Cr. Profit before tax showed fluctuations, with a high of 6.22 Cr in March 2024 but dropping to 4.83 Cr in March 2025. Profit after tax reached 3.64 Cr in March 2025, down from 4.50 Cr in March 2024, yet still a significant improvement from the loss of 0.01 Cr in March 2022. The company's total assets surged to 68.28 Cr in March 2025 from 4.63 Cr in March 2022, while total liabilities also increased to 68.28 Cr in March 2025, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved to 7.00 Cr in March 2025, and the closing cash and cash equivalents rose to 4.00 Cr, showcasing a positive cash position. Overall, Nephro Care's financial metrics indicate robust growth and operational scaling over the past few years.

Is Nephro Care overvalued or undervalued?

As of September 11, 2025, Nephro Care is considered expensive with a PE ratio of 74.28 and remains overvalued compared to peers, having underperformed the Sensex with a return of -35.06% over the past year.

As of 11 September 2025, Nephro Care's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its current financial metrics. The PE ratio stands at 74.28, the Price to Book Value is 5.06, and the EV to EBITDA ratio is 42.54, all of which are significantly higher than the industry averages.<BR><BR>In comparison to its peers, Nephro Care's valuation appears less favorable. For instance, Max Healthcare is categorized as very expensive with a PE ratio of 95.01, while Apollo Hospitals, considered fairly valued, has a PE ratio of 72.1. Despite this, Nephro Care's high valuation ratios suggest that it is overvalued relative to its peers. The company's stock has underperformed against the Sensex, particularly over the past year, with a return of -35.06% compared to the Sensex's modest gain of 0.35%.

Who are the top shareholders of the Nephro Care?

The top shareholder of Nephro Care is Pratim Sengupta, holding 60.71%, with individual investors owning 27.07% and 13 foreign institutional investors holding 3.5%. The highest public shareholder is Rohan Vinay Pai at 2.24%.

The top shareholders of Nephro Care include Pratim Sengupta, who is the promoter with the highest holding at 60.71%. The company has no pledged promoter holdings, and individual investors collectively hold 27.07% of the shares. Additionally, there are 13 foreign institutional investors (FIIs) that hold 3.5% of the company. The highest public shareholder is Rohan Vinay Pai, with a holding of 2.24%.

What is the technical trend for Nephro Care?

As of May 22, 2025, Nephro Care's trend is mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, with the stock underperforming the Sensex by -27.72% year-to-date.

As of 22 May 2025, the technical trend for Nephro Care has changed from sideways to mildly bearish. The daily moving averages indicate a bearish stance, while the weekly MACD is mildly bullish, suggesting mixed signals. The weekly Bollinger Bands and KST are both bearish, reinforcing the negative outlook. Additionally, the stock has underperformed the Sensex significantly year-to-date, with a return of -27.72% compared to the Sensex's 6.17%. Overall, the current stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands.

When is the next results date for Nephro Care?

No Upcoming Board Meetings

Has Nephro Care declared dividend?

No Dividend History Available